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Debate: This house believes that SBRT should become the 
standard of care for T1 and small T2 NSCLC tumours  
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The current standard of care for T1 and small T2 early-stage 
non-small cell lung cancer (NSCLC) is surgical resection with 
lobectomy and nodal sampling/resection. There is 
randomized evidence that wedge resection is an inferior 
operation to lobectomy [1] but no large series randomized 
evidence of surgery versus any other curative intervention for 
early stage lung cancer. In addition, for patients over 71 
years there may be no benefit of lobectomy over limited 
resection[2]. Stereotactic body radiotherapy (SBRT) is not a 
new treatment and has been used in medically inoperable 
stage I NSCLC for 20 years[3]. Given the very high rates of 
local control ~90% at 3-5 years[4], the low rates of acute 
toxicity and little detriment to quality of life post 
treatment[5] SBRT is now a standard of care for medically 
inoperable peripherally located T1 and T2 tumours up to 5cm 
in diameter. For medically operable patients where the risks 
of surgery are low, surgery does offer a theoretical 
advantage over local ablative treatment such as SBRT. 
Optimum surgery with removal or the tumour and 
surrounding lobe may remove occult cancer cells outside the 
treated volume that may not be included in the SBRT 
treatment volume. In addition, nodal resection may convey 
an additional survival benefit and for those patients with 
occult N1/2 disease those patients could further benefit with 
the addition of adjuvant chemotherapy.  
However, the average age at the time of diagnosis of lung 
cancer is 70, often in patient’s with significant medical co-
morbidity that precludes lobectomy and reduces the chance 
of them receiving adjuvant chemotherapy[6]. Surgical 
mortality at both 30 and 90 days increases with age further 
reducing the potential benefit from lobectomy and nodal 
sampling/resection[7]. In addition, with PET/CT staging and 
minimally invasive techniques (EBUS) for pathologically 
sampling the mediastinum now routine practice, the chance 
of missing occult N1/N2 nodal disease is small being <9% in 
one series[8].  
Propensity analysis of patients receiving surgery versus SBRT 
have been performed on retrospective series with some 
reports suggesting no difference in survival between the two 
match groups and others suggesting a benefit with surgery. 
Randomized controlled trials (RCT) of surgery versus SBRT 
(STARS/ROSEL) have been attempted but have been closed 
prematurely due to poor accrual. A recent pooled analysis of 
the STARS and ROSEL studies showed no significant difference 
between SBRT and surgery, though a trend for improved 
survival with SABR but this was based on 58 patients[9].  
Given the limited data from STARS/ROSEL and conflicting 
results from propensity matched analysis there is a need for 
successful randomized trials of surgery versus SBRT to prove 
whether SBRT should be the standard of care. Hopefully, the 
open SABRtooth (UK) and STABLE-MATES (USA) trial combined 
with other planned trials of SBRT versus surgery will recruit 
and provide the answer to this key question. 
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For early-stage non-small cell lung cancer (NSCLC) surgical 
resection remains the treatment of choice providing 
excellent long-term results (1). Recently, stereotactic body 
radiotherapy (SBRT) has become an alternative treatment for 
localized NSCLC (2). SBRT has mainly been applied for 
functionally in operable patients with severe 
cardiopulmonary morbidity. Currently, there is an ongoing 
debate whether SBRT is also a valid oncological treatment for 
low-risk patients who are operable from a technical and 
functional perspective. No large randomized studies are 
available directly comparing SBRT and surgical resection with 
systematic lymph node dissection. Several trials closed 
prematurely due to poor accrual.  
From a thoracic surgical point of view several concerns 
emerge when applying SBRT to operable early-stage NSCLC: 
precise pathology is not obtained in all cases, information on 
locoregional lymph node involvement is not always available 
making it difficult to recommend adjuvant chemotherapy in 
specific cases, and rather troublesome, different criteria are 
used when comparing results of surgery and SBRT, mainly in 
relation to local recurrence (3,4). Moreover, thoracic 
surgeons are more and more dealing with “salvage surgery” 
after previous radiotherapy when no other therapeutic 
options are available (5). Technically, these resections may 
be very challenging due to technical difficulties during 
dissection of the hilar region not encountered during primary 
intervention. These procedures should be performed in 
dedicated thoracic centres with a large experience.  
Due to the lack of clear evidence, different opinions are 
expressed in present-day literature.  
In a pooled analysis of two randomised trials comparing SBRT 
with lobectomy for stage I NSCLC that closed prematurely 
due to poor accrual, the authors concluded that SBRT can be 
considered a valid treatment option for operable stage I 
NSCLC (6). However, because of small patient sample size 
and short follow-up time, they indicate that further 
randomized studies should be performed before more 
definite recommendations can be made (6).  
A different conclusion was reached in a recent propensity 
score analysis matching 41 patients who underwent video-
assisted (VATS) lobectomy with 41 patients treated with SBRT 
for stage I NSCLC (7). Significant differences were found in 
overall survival, cause-specific survival, recurrence-free 
survival, local and distant control favouring VATS lobectomy. 
Conclusion of this study was that VATS lobectomy may offer a 
significantly better long-term outcome than SBRT in 
potentially operable patients with biopsy-proven clinical 
stage I NSCLC.  
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Another propensity score analysis compared SBRT with 
sublobar resection for stage I NSCLC in patients at high risk 
for lobectomy (8). In 53 matched pairs the difference in 
overall survival was not significant and the cumulative 
incidence of cause-specific death was comparable between 
both groups. Conclusion of this study was that SBRT can be an 
alternative treatment option to sublobar resection for 
patients with severe comorbidity who cannot tolerate 
alobectomy due to functional impairment (8).  
In June 2015 the “Comité del’Evolution des Pratiques en 
Oncologie (CEPO) from Québec, Canada published 
recommendations regarding the use of SBRT (9). For 
medically operable patients with T1-2N0M0 NSCLC surgery 
remains the standard treatment due to the lack of high-level 
evidence and valid comparative data. For medically 
inoperable patients withT1-2N0M0 NSCLC or medically 
operable patients who refuse surgery, SBRT should be 
preferred to external beam radiotherapy. In the latter cases 
a biological equivalent dose (BED) of at least 100 Gy should 
be administered. The choice ofusing SBRT should be 
discussed within a multidisciplinary tumor board. 
Radiotherapy should not be considered for patients whose life 
expectancy is very limited because of comorbidities.  
In summary, main points are: 
· surgical resection remains the treatment of choice for 
operable early-stage NSCLC  
· SBRT may be considered for functionally compromised 
patients who cannot tolerate lobectomy.  
· further high-level evidence is needed which requires close 
cooperation between radiation oncologists and thoracic 
surgeons to design comparative trials with clear inclusion 
criteria and unequivocal definitions of endpoints.  
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Debate: Is brachytherapy the best for partial breast 
irradiation?  
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Accelerated Partial Breast Irradiation (APBI) using 
multicatheter brachytherapy is an attractive treatment 
approach not only to shorten the course of radiation therapy 
from 3-6 weeks to 2-5 days but also to reduce significantly 
the radiation exposure to the breasts, the skin, the lung and 
particularly to the heart very effectively.  
Over the last 20 years different modalities of APBI have been 
introduced into clinical practice –multicatheter 
brachytherapy, single catheter brachytherapy, IORT 
techniques, different techniques of External Beam Radiation 
Therapy (EBRT). Unfortunately fact is that the results of APBI 
trials with IORT using intraoperative electrons or 50 kV 
photons have been negative. As well Vaidya et al. (TARGIT 
trial) as Veronesi et al. (ELIOT trial) reported high 5-year 
recurrence rate after IORT, namely 3.3%-4.4% in IORT groups 
versus statistically significant lower recurrence rates in 
control groups 0.4%-1.3%. Possibility of APBI using EBRT is of 
course very attractive, since this technique is broadly 
available and easy to perform. Unfortunately, hitherto 
reported results of phase 3 APBI trials using EBRT are either 
disappointing (RAPID trial) or with low statistical power 
(Olivotto et al., Livi et al.). On the contrary, during the last 
decade number of modern phase 2 and phase 3 APBI trials, 
using multicatheter interstitial brachytherapy for the delivery 
of APBI, have demonstrated favorable long-term local control 
rates and cosmetic outcomes, comparable to the results of 
whole breast irradiation (WBI). In the largest phase 3 
randomized non-inferiority GEC-ESTRO trial with sufficient 
statistical power (~1200 pts.), importantly using for APBI 
solely multicatheter interstitial brachytherapy in 5 days, 
after median follow-up of 6.6 years the 5-year local 
recurrence rates were 1.4% in the APBI arm, and 0.9% in the 
WBI arm (p=0.4), and 5-year disease-free and overall survival 
were 96-97% in the WBI group versus 97% in the APBI group - 
all events are without any statistical and clinical significance. 
The equivalence of local recurrence rates was evident in all 
age groups, in all histological subgroups and also independent 
of the type of systemic therapy. Thus it´s the first phase 3 
study proving non-inferiority of APBI in comparison to whole 
breast irradiation for selected early stage breast cancer 
patients. Undoubted is, that in the light of the landmark UK 
and Canadian trials comparing 5 versus 3 weeks of WBI the 
difference in total treatment time between WBI and APBI 
using multicatheter brachytherapy (4-5 days) has been 
partially diminished. However the difference between 3 
weeks of WBI versus 4-5 days of APBI still remains clinically 
and socio-economically relevant. Moreover, due to the 
extreme steep fall-off of dose of Iridum-192, the significant 
dose reduction of irradiated normal tissues (including the 
heart and skin) is a unique advantage of interstitial 
multicatheter brachytherapy, which is hardly ever achievable 
by other APBI techniques. The remaining, hitherto 
unreported ongoing APBI trials unfortunately use for APBI 
only different techniques of EBRT. The results of these trials 
will therefore particularly contribute to further fine-tuning of 
selection criteria and to precise requirements for quality 
assurance of EBRT-based APBI.  
In summary: At the present time only the long-term results of 
APBI using sole multicatheter brachytherapy for appropriate 
selected patients demonstrate impressive low local 
recurrence rates – similar as WBI, accompanying with 
excellent radiation protection of surrounding organs – better 
as WBI. Consequently “APBI used multicatheter 
brachytherapy is today a proven and valid alternative 
treatment option after breast conserving surgery, and can be 
offered for all low risk breast cancer patients in clinical 
routine”. 
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Over the past ten years the results of several clinical trials 
have been published, detailing various approaches of PBI. 
Among the different techniques used, IORT has increased 
rapidly in popularity, mainly in Europe, and up to date many 
thousands of women have been treated in clinical setting. 
IORT allows to realize a radiation dose to the index quadrant, 
eliminating the treatment to the tissue remote from the 
tumour bed, and using only one very high dose (20 Gy or 
more) in a single session. When single doses above certain 
thresholds of 10 Gy are given, some additional biological 
effects on tumor cell killing and from the surrounding 
microenvironment can be expected. IORT also represents the 
possibility of overcoming some constraints such as the 
accessibility to the centres of radiotherapy, the socio-
economic impact on the working life and on the personal 
habits of the patient. Another important advantage is the 
avoidance of the interactions with the systemic therapy, that 
may determine delays in the initiation or in the carrying out 
of the adjuvant treatment. These potential benefits must be 
balanced with the potential higher risk of recurrence within 
the untreated gland tissue in the same breast as well as the 
still unknown long-term results on survival and cosmesis. Two 
prospective randomized clinical studies establishing the role 
of IORT in clinical practice have been published up to now. A 
single-center study, named ELIOT, was performed at the 
European Institute for Oncology (EIO) in Milan, Italy. Patients 
with limited size tumor (2.5 cm) and age of 48 years or more 
were either randomized to a single dose of 21 Gy of IORT 
with electrons or to standard WBI. The local recurrence rate 
(LRR) at 5-years was higher in the experimental arm (4.4% 
